Publications by authors named "Lance Berman"

Claim this Profile
I
In vitro and clinical data demonstrate negligible risk of drug-drug interactions with opelconazole, a novel inhaled antifungal agent.
Lindsey M R Cass, John Ayrton, Roger J Brüggemann, Jerome Moore, Ubaldo Martin, Lance Berman

J Antimicrob Chemother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment of an allergic bronchopulmonary aspergillosis patient with inhaled antifungal opelconazole.
Lisa Nwankwo, P Lewis White, Simon Barry, Lindsey M R Cass, Alison B Murray, Lance Berman

J Allergy Clin Immunol Pract· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Food and Drug Administration Public Workshop Summary-Addressing Challenges in Inhaled Antifungal Drug Development.
Caroline J Jjingo, Shukal Bala, Ursula Waack, Mark Needles, Timothy J Bensman, Lance Berman

Clin Infect Dis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals.
Ali Abbara, Mike Ufer, Christine Voors-Pette, Lance Berman, Max Ezzati

Fertil Steril· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Approaches Towards a Functional Cure of HIV/AIDS.
Lucia Bailon, Beatriz Mothe, Lance Berman, Christian Brander

Drugs· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Novel Approaches Towards a Functional Cure of HIV/AIDS.
Lucia Bailon, Beatriz Mothe, Lance Berman, Christian Brander

Drugs· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
Bertram Pitt, George L Bakris, Matthew R Weir, Mason W Freeman, Mitja Lainscak, Lance Berman

ESC Heart Fail· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
Bertram Pitt, David A Bushinsky, Dalane W Kitzman, Frank Ruschitzka, Marco Metra, Lance Berman

ESC Heart Fail· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics.
Matthew R Weir, Martha R Mayo, Dahlia Garza, Susan A Arthur, Lance Berman

J Hypertens· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia.
Lingyun Li, Stephen D Harrison, M Jamie Cope, Craig Park, Lawrence Lee, Lance Berman

J Cardiovasc Pharmacol Ther· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Matthew R Weir, George L Bakris, Coleman Gross, Martha R Mayo, Dahlia Garza, Lance Berman

Kidney Int· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval.
Faiez Zannad, Patrick Rossignol, Wendy Gattis Stough, Murray Epstein, Maria de Los Angeles Alonso Garcia, Lance Berman

Int J Cardiol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia.
David A Bushinsky, Gordon H Williams, Bertram Pitt, Matthew R Weir, Mason W Freeman, Lance Berman

Kidney Int· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
Bertram Pitt, George L Bakris, David A Bushinsky, Dahlia Garza, Martha R Mayo, Lance Berman

Eur J Heart Fail· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
George L Bakris, Bertram Pitt, Matthew R Weir, Mason W Freeman, Martha R Mayo, Lance Berman

JAMA· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
Matthew R Weir, George L Bakris, David A Bushinsky, Martha R Mayo, Dahlia Garza, Lance Berman

N Engl J Med· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are high-risk hypertensive patients being prescribed concomitant statin therapy?: a retrospective cohort study.
Richard H Chapman, Allison A Petrilla, Lance Berman, Joshua S Benner, Simon S K Tang

Am J Cardiovasc Drugs· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.
Steven E Nissen, E Murat Tuzcu, Peter Libby, Paul D Thompson, Magdi Ghali, Lance Berman

JAMA· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis